Headline News

 

FDA approves Pfizer’s HYMPAVZI for two additional hemophilia A and B patient populations with significant unmet need

Posted on June 09, 2026

Lilly’s triple agonist retatrutide shows broad and substantial benefits across weight, blood sugar, knee pain and sleep apnea in Phase III trials

Posted on June 09, 2026

Lilly’s oral GLP-1 Foundayo outperforms comparators across three pivotal type 2 diabetes trials in A1C control and weight reduction

Posted on June 09, 2026

Ultomiris delivers significant proteinuria reductions in adults with IgAN throughout the I CAN Phase III trial

Posted on June 09, 2026

Elecoglipron GLP-1 RA, advances into Phase III and marks the next chapter in AstraZeneca’s cardiometabolic and kidney portfolio

Posted on June 09, 2026

Sanofi’s Sarclisa subcutaneous receives EU approval as the first anticancer therapy delivered through an on-body injector

Posted on June 09, 2026

Salanersen granted FDA breakthrough therapy designation for spinal muscular atrophy

Posted on June 09, 2026

Roche unveils the Liver Disease Panel, the first suite of certified algorithms to support chronic liver disease management

Posted on June 01, 2026

Lilly to present new data on Foundayo, Mounjaro, and retatrutide at the American Diabetes Association’s 86th Scientific Sessions

Posted on June 01, 2026

Lilly’s Retevmo cut the risk of disease recurrence or death by 83% as adjuvant therapy in people with early stage RET fusion positive lung cancer

Posted on June 01, 2026

US FDA pushes back decision date for SERENA-6 filing of camizestrant to allow review of additional data

Posted on June 01, 2026

Imfinzi approved in the US as the first and only immunotherapy combination for patients with BCG naïve, high risk non muscle invasive bladder cancer

Posted on June 01, 2026

CARES Phase III programme misses primary endpoint in overall light chain amyloidosis population, yet positions anselamimab as a potential first anti fibril therapy in kappa light chain amyloidosis

Posted on June 01, 2026

Seven year analysis from Pfizer’s LORBRENA CROWN trial delivers the longest progression free survival reported so far in advanced non small cell lung cancer

Posted on June 01, 2026

TALZENNA and XTANDI combination cuts radiographic disease progression risk by over half in metastatic prostate cancer

Posted on June 01, 2026